CJC-1295 + Ipamorelin vs Tesamorelin

CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog developed by ConjuChem Biotechnologies using drug affinity complex (DAC) technology to bind albumin and extend half-life from minutes to days. A published pharmacokinetic study (Teichman et al., 2006, Journal of Clinical Endocrinology & Metabolism) showed that CJC-1295 increased GH and IGF-1 levels in healthy subjects for up to 6 days after a single dose — this is the primary published human data. ConjuChem discontinued clinical development and the compound was never submitted to the FDA for approval.

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) identified in the late 1990s. The original pharmacology was published in the European Journal of Endocrinology (Raun et al., 1998), describing ipamorelin as a selective GH secretagogue with minimal effect on cortisol or prolactin release in animal models. Ipamorelin is not FDA-approved for any indication and has extremely limited published human clinical data.

The theoretical rationale for stacking CJC-1295 with ipamorelin is pathway complementarity: CJC-1295 stimulates the GHRH receptor while ipamorelin activates the ghrelin receptor (GHS-R1a), potentially producing greater combined GH release than either compound alone. No published clinical trial has tested this specific combination for safety or efficacy.

Both compounds are individually unapproved and the combination has no regulatory approval in any jurisdiction. The stack's popularity is driven by community protocol sharing, telehealth prescribing patterns, and research-chemical marketplace availability — not by clinical evidence. Products marketed as 'research use only' are subject to FDA enforcement, including warning letters to suppliers who make implied human-use claims.

Tesamorelin (brand name Egrifta) received FDA approval in 2010 for the reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy. It is the only GHRH or GHS-class peptide with current FDA approval. The FDA drug label documents the approved indication, administration route (subcutaneous injection), and safety profile.

The pivotal Phase 3 trial was published in the New England Journal of Medicine (Falutz et al., 2010; PMID 20879920), showing significant reduction in visceral adipose tissue (VAT) over 26 weeks in HIV patients with lipodystrophy. The trial population was HIV patients with lipodystrophy — the approval is specifically for this indication, not for general obesity, cosmetic fat loss, or anti-aging.

Tesamorelin is a stabilized GHRH analog; its mechanism involves stimulating endogenous GH release, which in turn increases lipolysis and reduces visceral fat accumulation. It uses the same GHRH receptor pathway as CJC-1295 but was engineered for drug development, passed FDA review, and has published Phase 3 clinical trial data.

Tesamorelin is accessed through the prescription drug channel — a licensed provider, a pharmacy, and clinical records. Some telehealth platforms prescribe tesamorelin for its FDA-approved indication or, in some cases, off-label. Any use outside the approved HIV-associated lipodystrophy indication is off-label.